Brief: Calithera Biosciences Announces Expansion Of Co's Ongoing Clinical Trial Evaluating Telaglenastat In Combination With Pfizer's Cdk 4/6 Inhibitor Palbociclib

Calithera Biosciences

04/11/2020 18:47

Nov 4 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES-  EXPANSION OF CO'S ONGOING CLINICAL
TRIAL
EVALUATING TELAGLENASTAT IN COMBINATION WITH PFIZER'S CDK 4/6
INHIBITOR PALBOCICLIB
    * CALITHERA BIOSCIENCES ANNOUNCES EXPANSION OF ONGOING
CLINICAL
TRIAL EVALUATING TELAGLENASTAT IN COMBINATION WITH PALBOCICLIB
(IBRANCE®)
    * CALITHERA BIOSCIENCES - PHASE 1/2 STUDY WILL EXPAND TO
INCLUDE
ADDITIONAL PATIENTS WITH PDAC WHOSE TUMORS HARBOR MUTATIONS IN
BOTH KRAS AND CDKN2A

Source text for Eikon:  ID:nGNX2tXxWW 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))